Dcf Advisers, LLC Argenx Se Transaction History

Dcf Advisers, LLC

$201 Million
Q2 2025

A detailed history of Dcf Advisers, LLC transactions in Argenx Se stock. As of the latest transaction made, Dcf Advisers, LLC holds 13,650 shares of ARGX stock, worth $10.9 Million. This represents 3.74% of its overall portfolio holdings.

Number of Shares

13,650

Previous 14,350 4.88%

Holding current value

$10.9 Million

Previous $8.49 Million 11.41%

% of portfolio

3.74%

Previous 4.35%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	SELL	$532.27 - $656.65 $372,589 - $459,655	-700 Reduced 4.88%	13,650 $7.52 Million
Q1 2025 May 08, 2025	SELL	$571.0 - $671.75 $3.23 Million - $3.8 Million	-5,650 Reduced 28.25%	14,350 $8.49 Million
Q2 2024 Aug 12, 2024	SELL	$356.01 - $451.55 $71,202 - $90,310	-200 Reduced 0.99%	20,000 $8.6 Million
Q1 2024 May 15, 2024	SELL	$356.95 - $413.29 $89,237 - $103,322	-250 Reduced 1.22%	20,200 $7.95 Million
Q4 2023 Feb 13, 2024	SELL	$338.91 - $506.01 $525,310 - $784,315	-1,550 Reduced 7.05%	20,450 $7.78 Million
Q3 2023 Nov 13, 2023	SELL	$369.35 - $548.43 $1.37 Million - $2.03 Million	-3,700 Reduced 14.4%	22,000 $10.8 Million
Q1 2023 May 15, 2023	BUY	$334.23 - $403.65 $233,961 - $282,555	700 Added 2.8%	25,700 $9.58 Million
Q3 2021 Nov 15, 2021	BUY	$295.0 - $350.58 $1.48 Million - $1.75 Million	5,000 Added 25.0%	25,000 $7.55 Million
Q2 2021 Aug 13, 2021	SELL	$257.11 - $319.92 $1.03 Million - $1.28 Million	-4,000 Reduced 16.67%	20,000 $6.02 Million
Q1 2020 May 12, 2020	BUY	$108.83 - $165.23 $217,660 - $330,460	2,000 Added 9.09%	24,000 $3.16 Million
Q4 2019 Feb 12, 2020	BUY	$106.59 - $164.21 $2.34 Million - $3.61 Million	22,000 New	22,000 $3.53 Million

Others Institutions Holding ARGX

# of Institutions

492

Shares Held

28.2M

Call Options Held

370K

Put Options Held

211K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $44.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dcf Advisers, LLC with notifications on news.

Account